New drug BAT8008 enters human testing for Hard-to-Treat cancers
NCT ID NCT05620017
First seen Feb 12, 2026 · Last updated Jun 13, 2026 · Updated 15 times
Summary
This study is testing an experimental drug, BAT8008, in about 182 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the highest safe dose, and see how the body processes it. This is an early-phase trial, so it focuses on safety and dosing rather than proving the drug works as a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Affiliated Cancer Hospital of Chongqing University
RECRUITINGChongqing, Chongqing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.